Skip to main content
  •   

    New Topical Drugs for IOP Control

    AAO 2018
    03:33
    Glaucoma, Medical Therapy

    In this interview from AAO 2018, Dr. Gail Schwartz describes 2 new glaucoma medications on the market: latanoprostene bunod (Vyzulta) and netarsudil (Rhopressa). She describes the mechanism of action, recommended dosing and contraindications for each drug.

    Relevant Financial Disclosures: Dr. Schwartz receives lecture fees from Aerie Pharmaceuticals and Dr. Lind is a consultant for Aerie Pharmaceuticals